Skip to main content
REYON PHARMACEUTICAL CO., LTD logo

REYON PHARMACEUTICAL CO., LTD — Investor Relations & Filings

Ticker · 102460 ISIN · KR7102460003 KO Manufacturing
Open in API
Filings indexed 225 across all filing types
Latest filing 2025-05-15 Interim / Quarterly Rep…
Country KR South Korea
Listing KO 102460

About REYON PHARMACEUTICAL CO., LTD

https://www.reyonpharm.co.kr/

REYON PHARMACEUTICAL CO., LTD. is a research-driven company engaged in the development and manufacturing of chemical and biopharmaceutical products. Its primary business areas encompass the production of Active Pharmaceutical Ingredients (APIs), a diverse portfolio of generic medicines, and contrast agents. The company leverages advanced synthesis know-how to supply high-value APIs to domestic and international partners. A key strategic focus is the development of next-generation biopharmaceuticals, including gene therapies for conditions like wet age-related macular degeneration and NK cell therapies for solid cancers. Reyon is also expanding its capabilities to offer contract development and manufacturing (CDMO) services for complex biologic drugs.

Recent filings

Filing Released Lang Actions
분기보고서 (2025.03)
Interim / Quarterly Report Classification · 1% confidence The document is a '분기보고서' (Quarterly Report) for Reyon Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to March 31, 2025. It contains detailed financial information, business operations, management analysis, and governance details, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2025
2025-05-15 Korean
전환가액ㆍ신주인수권행사가액ㆍ교환가액의조정(안내공시)
Share Issue/Capital Change Classification · 1% confidence The document is a regulatory filing from a Korean company (Lee-on Pharmaceutical) regarding the adjustment of the conversion price of convertible bonds due to a decline in market price. This type of disclosure is a standard corporate action related to capital structure and financing instruments. Among the provided categories, 'CAP' (Capital/Financing Update) is the most accurate fit as it covers updates on financing activities and capital structure changes, specifically regarding convertible debt instruments.
2025-04-25 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is an official report of the results from a General Meeting of Shareholders (Annual General Meeting). It details the approval of financial statements, board appointments, and other resolutions passed during the meeting held on 2025-03-28. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA).
2025-03-28 Korean
[기재정정]사업보고서 (2024.12)
Annual Report Classification · 1% confidence The document is a formal 'Correction Report' (정정신고) for a previously filed 'Business Report' (사업보고서), which is the Korean equivalent of an Annual Report (10-K). It explicitly lists corrections to financial statements (Income Statement, Cash Flow Statement, Balance Sheet) and internal control evaluation dates. Since it is a formal amendment to the primary annual financial filing, it is classified under the 10-K category. FY 2024
2025-03-24 Korean
감사보고서제출
Audit Report / Information Classification · 1% confidence The document is a regulatory filing titled '감사보고서 제출' (Submission of Audit Report) from Lee-Yoon Pharmaceutical. It provides a summary of the audit opinion (unqualified/proper) and key financial data (assets, liabilities, revenue, net income) for both consolidated and separate financial statements. While it contains audit-related information, it is a standard regulatory disclosure announcement (DART filing) summarizing the audit results rather than the full, multi-page audit report document itself. Given the structure and the nature of the disclosure, it fits best as a Regulatory Filing (RNS) or a Report Publication Announcement (RPA). Since it is a formal regulatory disclosure of the audit results, RNS is the most appropriate classification. FY 2024
2025-03-20 Korean
사업보고서 (2024.12)
Audit Report / Information Classification · 1% confidence The document is a comprehensive 'Consolidated Audit Report' (연결감사보고서) for Lee-Yoon Pharmaceutical (이연제약) for the fiscal year ending December 31, 2024. It includes the independent auditor's report, consolidated financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes. This is a formal, full-year financial audit report, which falls under the 'Audit Report / Information' category. FY 2024
2025-03-20 Korean

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.